Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)

Mandaliya et al. (Sun,) studied this question.

www.synapsesocial.com/papers/69df19c3d5404a0bea591ef8 — DOI: https://doi.org/10.21037/tlcr.2019.11.16

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer· 2012 · 300 citations
2. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer· 2003 · 778 citations
3. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet· 2014 · 67 citations
4. Greater risks of chemotherapy toxicity in elderly patients with cancer.· 2004 · 205 citations
5. Inflammation and cancer: back to Virchow?· 2001 · 7,654 citations